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The lytic cycle functions of gammaherpesviruses have received relatively little attention to date, at least in
part due to the lack of a convenient experimental model. The murine gammaherpesvirus 68 (MHV-68) now
provides such a model and allows the roles of individual lytic cycle gammaherpesvirus proteins to be evaluated
in vivo. We have used MHV-68 to determine the contribution of a gammaherpesvirus thymidine kinase (TK)
to viral lytic replication and latency establishment. MHV-68 mutants with a disrupted TK gene grew normally
in vitro but showed a severe attenuation of replication in the lungs after intranasal inoculation, with lytic titers
at least 1,000-fold lower than those of wild-type and revertant viruses. Nevertheless, the establishment of
latency by the TK-deficient mutants, while delayed, was not prevented by their lytic replication deficit. The viral
TK clearly plays a crucial role in the capacity of MHV-68 to replicate efficiently in its natural host but does not
seem to be essential to establish a persistent infection. The potential of TK-deficient mutants as gammaher-
pesvirus vaccines is discussed.
Any rational approach to controlling herpesvirus infections
depends on understanding how individual viral genes contrib-
ute to pathogenesis. This can be predicted to only a very
limited degree from biochemical analysis in vitro. Neither of
the human gammaherpesviruses, Epstein-Barr virus (EBV)
and the Kaposi’s sarcoma-associated herpesvirus (KSHV),
readily infects nonprimates. However, murine gammaherpes-
virus-68 (MHV-68) is a natural parasite of small rodents that is
genetically related to the human gammaherpesviruses (10, 37)
and affords a direct means to approach the in vivo complexities
of gammaherpesvirus biology in conventional mice. After in-
tranasal inoculation, MHV-68 replicates lytically in the respi-
ratory tract. It then spreads to lymphoid tissue, where there is
a massive expansion of latently infected B cells, associated with
a virus-driven immune activation syndrome reminiscent of the
infectious mononucleosis illness induced by EBV (8, 22). Non-
antigen-specific B-cell activation and an expansion of the
CD8 V4M T-cell subset are prominent features (25, 26,
34). Latent virus declines to a lower level after the infectious
mononucleosis illness but persists for life.
Herpesviruses usually infect cells that are not cycling, and
therefore they must cope with an intracellular milieu deficient
in deoxyribonucleotides. Since dTTP cannot be derived from
intracellular ribonucleotide pools by ribonucleotide reductase,
its supply presents a special problem. Cellular dTMP either is
synthesized de novo, culminating in dUMP methylation by
thymidylate synthase, or is salvaged from dT by thymidine
kinase (TK). In most cell types the salvage pathway predomi-
nates, and TK is the rate-limiting enzyme in dTMP supply. The
major (nonmitochondrial) cellular TK turns over rapidly and is
induced only at the time of DNA synthesis (7). Cellular thy-
midylate synthase activity is similarly regulated. The supply of
dTMP is thus limited to the S phase of the cell cycle. To
compensate for the lack of dTMP in infected cells, all herpes-
viruses increase intracellular TK activity and most encode a TK
homolog. The sequence conservation of the genes encoding
herpesvirus TKs is fairly low, and none is closely related to the
cellular gene—they may originate instead from the cellular
deoxycytidine kinase (17). The herpes simplex virus (HSV) TK
has been studied most intensively, and its relatively broad
specificity for nucleoside analogues has made it the archetype
for succesful antiviral chemotherapy. Since TK-deficient viral
mutants are not uncommon, the basis for this approach has
been the failure of these mutants to replicate in neurons (9, 12,
13). TK-deficient HSV also shows reduced replication in epi-
thelial sites (9).
While the alpha- and betaherpesviruses cause disease by
lytic replication, the human gammaherpesviruses cause disease
chiefly when latent. However, two factors have focused atten-
tion on gammaherpesvirus TKs. First, the presence of repli-
cating KSHV in tumors associated with this virus suggests that
lytic cycle viral genes contribute to disease progression (19)
and are thus potential therapeutic targets; and second, the
induction and simultaneous inhibition of lytic cycle EBV rep-
lication is being developed as a strategy to clear latent genomes
(11). How the gammaherpesvirus TKs function is not entirely
clear. They have in common a large N-terminal extension, not
present in the HSV TK, which, with EBV at least, is not
required for TK activity (20). Also, the KSHV TK has, outside
the context of viral infection, a suprisingly high Km for thymi-
dine (16). Its activity may be higher, or even qualitatively
different, in virus-infected cells. Interestingly, the pathogenic-
ity of herpesvirus saimiri, another gammaherpesvirus, is in-
creased by expression of the HSV TK (18).
The MHV-68 TK gene has early and late kinetics and en-
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codes a protein with TK activity in vitro (24). The MHV-68 TK
has already been exploited in antiviral chemotherapy: treating
mice with nucleoside analogues (3, 23, 33) inhibits lytic
MHV-68 replication but does not prevent the establishment of
a latency. However, the TK status of the viruses establishing
latency was not determined. Consequently, it is not clear
whether the limited capacity of antiviral chemotherapy to con-
trol host colonization reflected a limited potency and delivery
of the nucleoside analogs tested or reflected the capacity of
naturally occurring TK mutants to replicate in vivo. Since viral
TK mutants are likely to arise on a regular basis, a knowledge
of the importance of TK in pathogenesis should help to define
the theoretical limit of efficacy of TK-based antiviral chemo-
therapy. In addition, the basic biological role of TK in gam-
maherpesvirus infections is unknown. To address these ques-
tions, we have generated and characterized TK-deficient
MHV-68 mutants.
MATERIALS AND METHODS
Mice. Female BALB/c and C57BL/6 mice were purchased from Harlan U.K.
Ltd. (Bicester, United Kingdom) and housed at the Biological Services Unit of
the Cambridge University School of Veterinary Sciences. All procedures were
carried out in accordance with Home Office Project Licence 80/1579. Mice were
infected intranasally at 6 to 8 weeks of age with 2  104 PFU of virus in a volume
of 30 l.
Cell lines. Baby hamster kidney (BHK-21) cells (American Type Culture
Collection, CCL-10), a TK-deficient derivative (European Collection of Animal
Cell Cultures, catalogue number 85011423), and murine embryonic fibroblasts
harvested at 13 to 14 days of gestation were all grown in Dulbecco modified
Eagle medium (Invitrogen, Paisley, United Kingdom) supplemented with 2 mM
glutamine, 100 U of penicillin per ml, 100 g of streptomycin per ml, and 10%
fetal calf serum (PAA Laboratories, Linz, Austria) (complete medium). The
phenotype of TK and TK BHK-21 cells was confirmed by selection in medium
supplemented with 50 g of 5-bromo-2-deoxyuridine per ml and 100 M hypo-
xanthine–0.4 M aminopterin–16 M thymidine medium, respectively, prior to
use. To make NIH 3T3 CRE cells, the cre gene of bacteriophage P1 was cloned
into the EcoRI-XhoI sites of pMSCV-NEO (28) and cre-expressing retrovirus
was generated by transient transfection of Phoenix-Eco cells (www.stanford.edu
/group/nolan) with pMSCV-CRE-NEO. NIH 3T3 cells (American Type Culture
Collection, CRL-1658) were transduced with retrovirus in the presence of 6 g
of polybrene per ml and selected in 1 mg of G418 per ml.
Virus titers. Lungs were homogenized in complete medium, frozen, thawed,
and sonicated. Tissue debris was pelleted by brief centrifugation (1,000  g for
1 min). Infectious virus in homogenate supernatants was measured by a plaque
assay of 10-fold dilutions of lung homogenates on TK BHK-21 cells as previ-
ously described (31). After 5 days, monolayers were fixed in 10% formaldehyde
and stained with 0.1% toluidine blue and plaques were counted under a plate
microscope. Latent virus was measured by explant culture of single-cell suspen-
sions of spleens on murine embryonic fibroblast monolayers, which were fixed
and stained after 6 days.
Viral mutagenesis. A kanamycin resistance gene flanked by Flp recombinase
target (FRT) sites was amplified from BsaI-linearized pCP15 (1) by PCR (Ex-
pand Hi Fidelity; Roche, Lewes, United Kingdom), using primers with 50-bp 5
extensions corresponding to nucleotides 33251 to 33300 and 33451 to 33500 of
the MHV-68 genome (37). The purified PCR product was electroporated into
the SbcA RecBC Escherichia coli strain JC8679 containing the MHV-68 bacterial
artificial chromosome (BAC). This allowed incorporation of the kanamycin
resistance gene into the MHV-68 BAC TK locus by RecE/T-mediated recombi-
nation (1). BAC DNA (TK Kan) was isolated from chloramphenicol- and
kanamycin-resistant colonies and transformed into E. coli DH10B. The integrity
of the BAC and correct incorporation of the kanamycin resistance gene were
confirmed by restriction enzyme mapping. E. coli DH10B containing the TK
Kan BAC were then transformed with a temperature-sensitive Flp recombinase
expression plasmid, pCP20, as previously described (1). This resulted in excision
of the kanamycin resistance gene, leaving a 167-bp insert in the TK locus,
comprising a single FRT site and short flanking plasmid sequences, in place of
150 bp of viral genome (TK Kan). The bacteria were cured of pCP20 by
growth at the nonpermissive temperature (43°C). Successful Flp recombination
was established by replica plating of bacteria onto chloramphenicol or chloram-
phenicol plus kanamycin and confirmed by restriction enzyme mapping of BAC
DNA. To make a revertant virus (TK R), a BamHI-SacI unmutated MHV-68
genomic fragment (genomic coordinates 29616 to 35045) was ligated into the
RecA SacB temperature-sensitive shuttle vector pST76K-SR (1) and trans-
formed into E. coli DH10B containing the TK Kan BAC. Cointegrants were
selected by growth in chloramphenicol plus kanamycin at 43°C. Cointegrant
resolution was selected by growth in chloramphenicol–5% sucrose at 30°C; under
these conditions, the induced expression of SacB is lethal to E. coli. Colonies
were then screened by restriction enzyme digestion for resolution to a wild-type
(WT) genomic pattern. An independent TK-deficient mutant was also made by
the pST76K-SR shuttle method. An EcoRI-restricted MHV-68 genomic frag-
ment (genomic coordinates 30798 to 38212) was cloned into pUC8. The central
portion (33293 to 34300) of the TK open reading frame (ORF) (32879 to 34813)
was excised by digestion with AvrII and PmeI, blunting with T4 DNA polymerase
(New England Biolabs, Hitchin, United Kingdom), and religation with T4 DNA
ligase (New England Biolabs). This modified genomic fragment was then excised
with EcoRI, blunted with T4 DNA polymerase, and subcloned into SmaI-cut
pST76K-SR. This plasmid was transformed into E. coli DH10B containing the
WT MHV-68 BAC. RecA-mediated plasmid integration into the BAC and
cointegrant resolution proceeded as described above, except that colonies were
screened for retention of the mutant TK locus in the BAC rather than for the
WT pattern. Each BAC was reconstituted into MHV-68 virus by transfecting 10
g of BAC DNA into NIH 3T3 cells by the calcium phosphate method (Invitro-
gen). The loxP-flanked BAC-green fluorescent protein cassette was then re-
moved by the passage of virus through NIH 3T3- CRE cells until green fluores-
cent protein-positive cells were no longer visible.
TK assay. TK BHK-21 cells were infected with MHV-68 (5 PFU per cell).
After 20 h, the cells were harvested, washed with ice-cold phosphate-buffered
saline (PBS), pelleted, resuspended in 50 mM NaCl, and sonicated for 45 s on
ice. Cell debris was removed by ultracentrifugation at 25,000  g for 30 min at
4°C. Supernatants were stored at 70°C. To assay thymidine phosphorylation,
supernatants were incubated at 37°C for 20 min in 0.1 M phosphate buffer (pH
6.4)–4.8 mM MgCl2–4.8 mM ATP–11 M [14C]thymidine (58 Ci/mol; Amersham
Biosciences, Little Chalfont, United Kingdom). Samples were then boiled for 2
min, spotted in duplicate onto DEAE paper, and allowed to dry. Free thymidine
was removed by washing three times for 1 h each in 5 mM ammonium formate.
Bound phosphorylated thymidine was quantified by scintillation counting.
Flow cytometry. Spleens were disrupted into single-cell suspensions, washed in
PBS–0.1% bovine serum albumin (BSA)–0.01% azide, and incubated for 30 min
on ice with 5% mouse serum, 5% rat serum, and anti-CD16/32 monoclonal
antibody (BD-Pharmingen, San Diego, Calif.). Specific staining was done with
phycoerythrin-conjugated anti-CD8 and fluorescein isothiocyanate-coupled anti-
V4 (BD-Pharmingen). After a 1-h incubation on ice, cells were washed twice in
PBS–0.1% BSA–0.01% azide and analyzed on a FACSCalibur instrument using
Cellquest software (Becton-Dickinson, Oxford, United Kingdom). Data were
analyzed with FCSPress v1.3.
ELISA. Maxisorp enzyme-linked immunosorbent assay (ELISA) plates (Nalge
Nunc, Rochester, N.Y.) were coated overnight with goat anti-mouse immuno-
globulin G (IgG) for total IgG measurements and with 0.05% Triton X-100-
disrupted MHV-68 virions for virus-specific IgG as previously described (26).
The plates were washed three times with PBS–0.1% Tween 20, blocked with
PBS–0.1% Tween 20–1% BSA, and incubated with threefold serum dilutions for
1 h at room temperature. They were then washed four times, incubated with
alkaline phosphatase-conjugated goat anti-mouse IgG, washed five times, and
developed with nitrophenyl phosphate substrate (Sigma Chemical Co., Poole,
United Kingdom). The reaction was terminated with an excess of NaOH, and the
absorbance was read at 405 nm.
Analysis of viral transcripts. RNA was extracted from MHV-68-infected cells
using RNAzolB (Tel-Test, Friendswood, Tex.), and contaminating DNA was
removed with RNase-free DNase (Promega UK, Southampton, United King-
dom). cDNA was synthesized using avian myeloblastosis virus reverse transcrip-
tase (RT) (Promega) and amplified with Taq polymerase (Amersham Bio-
sciences) and primers specific for the MHV-68 ORF20 (genomic coordinates
32117 to 32871), ORF22 (34883 to 35396), and M3 (6061 to 7278). The PCR
products were analyzed over a range of cycle numbers to ensure a more quan-
titative comparison of transcript levels.
RESULTS
Generation of MHV-68 TK mutants. The translation start
site for the MHV-68 TK is uncertain. It probably corresponds
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to the start of the TK ORF (genomic coordinate 32879) but
could alternatively be at one of two downstream ATG codons
(32984 and 33128). These lie within the relatively poorly con-
served N-terminal extension that is characteristic of gamma-
herpesvirus TKs and are some distance from the conserved
nucleoside and nucleotide binding sites (33860 onward). For
this reason, the TK ORF was disrupted at genomic coordinate
33300, thereby minimizing the chance of internal initiation of
translation to create a functional TK protein (Fig. 1A). A
deletion mutant (TK-DEL) lacking the bulk of the TK ORF,
including the conserved motifs related to TK function, was also
generated for comparison. In each case the N-terminal and
C-terminal ends of the TK ORF were preserved, since these
probably contain promoter elements for the neighboring genes
(ORF20 and the glycoprotein H gene, respectively).
The genomic structures of all TK mutants, as well as a
revertant of the TK Kan mutant, were checked by restric-
tion enzyme mapping of BAC DNA (data not shown) and by
Southern blot analysis of viral DNA (Fig. 1B). This confirmed
the expected pattern of genomic changes. The precise insertion
site of the kanamycin resistance cassette was further checked
by DNA sequencing of PCR products amplified from viral
DNA and was found to replace nucleotides 33301 to 33450 of
the viral genome as predicted. DNA sequencing also estab-
FIG. 1. Genomic structure of TK and TK viruses. (A) The TK Kan virus was generated by inserting a FRT-flanked kanamycin resistance
gene at genomic coordinates 33301 to 33450. The kanamycin resistance coding sequence was removed by Flp recombination to leave an inset of
167 bp (TK Kan). This virus was reverted by homologous recombination with an unmutated genomic segment (TK R). An independent mutant
(TK Del) was generated by RecA-mediated recombination of BAC DNA with a genomic plasmid clone in which genomic coordinates 33293 to
34300 are deleted by digestion with AvrII and PmeI. (B) Viral DNA was digested with XbaI, EcoRI, or SacI, electrophoresed, blotted, and probed
with a32P-labeled genomic EcoRI fragment spanning the TK locus.
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lished the presence of multiple in-frame stop codons in the TK
ORF of the TK Kan virus and accurate reconstitution of the
TK coding sequence in the TK R revertant virus.
Characterization of MHV-68 TK mutants in vitro. TK assays
(Fig. 2) were used to confirm that mutagenesis had disrupted
the viral TK gene and that reversion had successfully restored
it. The MHV-68 TK is expressed at early times (24) and is
presumably most necessary prior to viral DNA replication.
Therefore, we wished to check particularly whether there was
TK activity in cells at early times after infection with the TK
mutants. To do this, TK BHK cells were infected with TK
and TK viruses (5 PFU/cell) in either the presence or absence
of phosphonoacetic acid, which inhibits viral DNA replication
and thus limits gene expression to the early lytic cycle. Cultures
were harvested after 18 h and assayed for TK activity. No
activity was seen in cells infected with the TK mutants, either
early or late in lytic cycle replication, whereas activity was fully
restored in the revertant virus.
The capacity of TK viruses to replicate in vitro was assayed
after low-multiplicity infection (0.01 PFU/cell) of TK
BHK-21 cells (Fig. 3A). No significant deficit in the growth of
the TK mutant viruses was observed. A similar pattern of
growth was seen in TK BHK-21 cells (data not shown). In
each case, the TK-deficient viruses were probably exploiting
preexisting deoxyribonucleotide pools. (The de novo synthesis
pathway provides dTMP in TK BHK-21 cells.) In an attempt
to reduce these pools, MEFs were grown to passage 9 prior to
low-multiplicity infection with TK and TK viruses. At this
time, their growth was considerably slowed, indicated impend-
ing senescence and thus cessation of DNA synthesis. Surpris-
ingly, the TK viruses showed only a minor growth deficit
compared to the TK viruses in the aged MEFs (Fig. 3B), and
this result was confirmed in a repeat experiment. The residual
dTMP pools in senescent MEFs were presumably still suffi-
cient for viral replication, although MHV-68 may also stimu-
late senescent MEFs to reenter the cell cycle.
Growth of MHV-68 TK mutants in vivo. We initially com-
pared the capacity of BAC WT and TK Kan MHV-68 to
grow in vivo after intranasal infection of BALB/c mice. Infec-
tious and latent viral loads in lungs and spleens were assayed
over the subsequent 3 weeks (Fig. 4A). The TK Kan virus
was severely impaired in lytic growth in the lungs. It also
showed reduced levels of latency at early time points (Fig. 4B),
and the splenomegaly and lymphadenopathy that normally ac-
company the establishment of MHV-68 latency were greatly
reduced (data not shown). However, despite the severe reduc-
FIG. 2. TK activity of TK and TK viruses. TK BHK-21 cells
were infected overnight with MHV-68 (5 PFU/cell) either in the ab-
sence of inhibitors (A) or with 100 g of phosphonoacetic acid per ml
(B), to inhibit progression to late viral gene expression. dT phosphor-
ylation was assayed by the addition of [14C]thymidine to cell lysates
followed by binding to DEAE paper, washing, and scintillation count-
ing. “background” represents counts with substrate but no cell lysate.
Means and standard deviations for triplicate assays are shown. Similar
results were obtained in two further experiments.
FIG. 3. Growth of TK and TK viruses in vitro. TK BHK-21 cells (A) or passage 9 MEFs (B) were infected with MHV-68 (0.01 PFU/cell).
Cultures were subjected to titer determination for infectious virus by plaque assay on TK BHK-21 cells.
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tion in lytic replication at the site of primary infection, some
TK-deficient virus was still able to seed to lymphoid tissue and
establish latency. Further infections of C57BL/6 mice revealed
a very similar lytic replication deficit in all the TK mutants
and full reversion of the TK R virus (Fig. 4C). Thus, the lytic
replication deficit was firmly linked to the TK locus.
Transcription of viral genes adjacent to TK. ORF20,
ORF21, and ORF22 are tightly packed in the viral genome,
and it is likely that the promoters for ORF20 and ORF22,
which are both orientated away from ORF21 (the MHV-68 TK
gene), have their promoter elements within the TK coding
sequence. For this reason, each TK mutation was made at least
400 bp away from the start of either neighboring ORF. The
fact that no significant in vitro growth deficit was observed with
the MHV-68 TK mutants implied that normal transcription of
ORF20 and ORF22 was maintained, since such a deficit is seen
with a disruption of either HSV homolog. Furthermore, there
was no difference in phenotype between the small-insertion
(TK Kan), large-insertion (TK Kan), and large-deletion
(TK Del) TK mutants.
To compare ORF20 and ORF22 transcripts with the TK
and TK viruses, cDNA was generated from BHK-21 cells
infected overnight with each mutant (5 PFU/cell) and ampli-
fied by PCR with ORF-specific primers. The reaction products
were analyzed over a range of 24 to 30 cycles. This semiquan-
titative RT-PCR analysis showed no evidence of an effect of
TK mutagenesis on the transcription of either ORF20 or
ORF22 (Fig. 5).
Antiviral immunity elicited by TK mutants. The decreased
lytic replication observed with the TK mutants suggested that
these viruses—or others deficient in lytic replication—might
provide the basis for gammaherpesvirus vaccines. To explore
this possibility further, we analyzed the TK mutants for a
desirable characteristic, their immunogenicity, and an undesir-
able one, their capacity to establish latency. The course of TK
Kan virus replication in BALB/c mice (Fig. 4) suggested that
although early-latency titers were reduced, they might eventu-
ally reach those of the BAC WT virus. This proved to be the
case, and 1 month after infection, splenic latency titers were
equivalent in TK and TK viruses (Fig. 6A). Measurements
of latency-associated immune activation–non-antigen-specific
B-cell activation and expansion of the CD8 V4 T-cell sub-
set—showed a reduction associated with the TK mutants com-
pared to the BAC WT and TK R viruses but showed consid-
erable variation between individual mice (Fig. 6B and C). This
supported the idea that latency establishment, with its accom-
panying infectious mononucleosis-like illness, was delayed but
not prevented by the deficit in lytic virus replication. There was
a similar spread in virus-specific antibody responses between
mice infected with TK viruses, which generally correlated
with the level of the nonspecific response. Thus, it appeared
that defective lytic replication led to a low antigen load and
consequently to poor immunogenicity; latency amplification
increased the viral load and improved immunogenicity, but at
the cost of viral persistence.
DISCUSSION
Disruption of the MHV-68 TK had little effect on viral
growth in vitro but caused a marked attenuation of lytic rep-
lication in vivo. This delayed but did not prevent the establish-
ment of latency. Thus, viruses largely defective in lytic repli-
cation were still able to persist and to drive an infectious
mononucleosis-like illness. The implication is that disrupting
lytic viral genes in human gammaherpesviruses, which cause
mainly latency-associated disease, is unlikely to prove a good
strategy in the generation of attenuated vaccine strains. Simi-
larly, the capacity of latency amplification to compensate for a
FIG. 4. Growth of TK and TK viruses in vivo. BALB/c (A and
B) or C57BL/6 (C) mice were infected intranasally with 2  104 PFU
of MHV-68. (A and C) Infectious virus in lung homogenates was
subjected to titer determination by a plaque assay on TK BHK-21
cells. (B) Latent virus in spleens was subjected to titer determination
by infectious center assay on passage 4-5 MEFs. In panels A and B,
BAC WT virus (E) was compared with TK Kan (F). In panel C, all
five viruses were compared. Means and standard errors of the mean (n
 6) are shown.
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defect in lytic replication probably limits the potential of TK-
dependent chemotherapy in gammaherpesvirus infections.
TK-deficient HSV was initially thought to have an in vitro
growth deficit; only later was this attributed to a deletion of the
overlapping UL24 gene (9). Clearly there is potential for con-
fusion when mutating this tightly packed region of the herpes-
virus genome. To allow for this, we generated three mutants,
using sites well away from the neighboring ORFs. The mutants
had similar phenotypes involving a severe in vivo lytic replica-
tion deficit with a relative preservation of latency establish-
ment. None showed decreased transcription of ORF20 (the
MHV-68 homolog of UL24) or of ORF22 (which encodes
glycoprotein H). Furthermore, there was no evidence of a
replication deficit in BHK-21 cells, as would be expected with
a disruption of either flanking gene.
TK-deficient MHV-68 showed a more severe epithelial rep-
lication deficit in vivo than did TK-deficient HSV (9). This may
reflect a difference in tropism or a difference in experimental
conditions. Epithelial surfaces encompass a wide range of cell
phenotypes, which differ in their progress through the cell
cycle, most obviously from replicating basal cells to terminally
differentiated superficial cells. Experimental HSV inoculation
typically involves skin scarification or subcutaneous injection,
both of which expose basal epithelial cells and, by causing
injury, stimulate cell division. After intranasal inoculation,
MHV-68 encounters only the most superficial and thus the
most fully differentiated cells of the intact epithelium. These
cells have generally exited from the cell cycle and presumably
contain little dTMP. TK is thus likely to be of particular im-
portance in the first cycles of virus replication. The almost
complete absence of lytic replication of TK viruses in the
lungs indicated that the availability of dTMP limits MHV-68
replication in vivo and that other viral functions, such as an
induction of cellular enzymes, cannot compensate for a lack of
TK.
In contrast to HSV, which cannot reactivate from latency in
the absence of TK, there was no obvious deficit in MHV-68
reactivation. Latency titers showed less TK-associated deficit
than did lytic titers, and TK viruses reached WT latency levels
by 1 month after infection. This presumably reflects differences
in cell tropism between alpha- and gammaherpesviruses: while
HSV is latent in terminally differentiated neurons, MHV-68 is
latent in B cells, macrophages, and dendritic cells (14, 32, 38),
all of which can proliferate in vivo. After intranasal MHV-68
infection of immunocompetent mice, B cells constitute the
major reservoir of recoverable latent virus (32). The amplifi-
cation of MHV-68 in germinal-center B cells (5) suggests that,
as with EBV (2), latent MHV-68 resides in the memory B-cell
pool. However, murine memory B cells normally proliferate at
a low rate (15) and so should rarely contain significant amounts
of dTMP. It may be that MHV-68 induced latently infected B
cells to enter the S phase during viral reactivation, at least
under the conditions of the infectious assay, such that a TK
deficit was not important.
FIG. 5. Viral transcription in TK and TK viruses. TK BHK-21 cells were infected with MHV-68 (5 PFU/cell), and 18 h later RNA was
extracted, reverse transcribed, and assayed for viral transcripts by RT-PCR amplification of part of each gene. Ethidium bromide-stained
electrophoresed PCR products are shown. ORF20 and ORF22 (encoding glycoprotein H) flank the TK gene of MHV-68. M3 is a control early-late
viral gene located 25 kb from the TK locus. (A) The specificity of each PCR amplification was confirmed by 30 cycles of amplification using BAC
DNA (lane ) and cDNA from uninfected cells (lane ). Lanes 1 to 5 are RT controls to exclude the presence of residual viral DNA, and lanes
6 to 10 are RT cDNA samples from cells infected with BAC WT (lanes 1 and 6), TK R (lanes 2 and 7), TK Kan (lanes 3 and 8), TK Kan
(lanes 4 and 9), and TK Del (lanes 5 and 10) viruses. (B) To gain a more quantitative idea of ORF20 and ORF22 transcription, the same samples
were amplified over a limiting number of cycles (24 to 30 cycles, as indicated).
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The capacity of TK-deficient viruses to drive latency ampli-
fication, with its attendant infectious mononucleosis-like ill-
ness, implied that this process is independent of lytic replica-
tion. This is consistent with data showing an independence of
lytic and latent virus amplification with drug treatment (3),
CD8 T-cell vaccination (21, 27), and antibody-mediated pro-
tection (30). CD8 T-cell vaccination with a latency epitope
has also so far proved ineffective in preventing the establish-
ment of latency (35), perhaps reflecting the action of viral
evasion genes such M3 and K3 (4, 6, 29, 36). It seems that
successful antiviral therapy must tackle both lytic and latent
replication in order to be effective in reducing host coloniza-
tion.
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